Publication date: Jun 01, 2026
In Australia, high pneumococcal conjugate vaccine (PCV) coverage has been achieved, yet invasive pneumococcal disease (IPD) continues to cause a significant burden of disease. The epidemiology of IPD was altered by the nonpharmaceutical interventions (NPIs) used to control the coronavirus disease (COVID-19) pandemic. We aimed to analyze this impact on the clinical characteristics associated with IPD in Australian children. We systematically evaluated the clinical and microbiological characteristics of IPD in children (
Open Access PDF
| Concepts | Keywords |
|---|---|
| Australia | child health |
| Children | invasive pneumococcal disease |
| Coronavirus | pneumococcus |
| Epidemiology | pneumonia |
| Pcv | viral co-infection |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Pneumococcal Disease |
| drug | DRUGBANK | Penciclovir |
| pathway | KEGG | Coronavirus disease |
| disease | MESH | COVID-19 |
| disease | MESH | co-infection |
Original Article
(Visited 4 times, 1 visits today)